Medicus Pharma Ltd. (MDCX.V)
| Previous Close | 2.1100 |
| Open | 2.1400 |
| Bid | 2.1300 x N/A |
| Ask | 2.2000 x N/A |
| Day's Range | 2.1400 - 2.1500 |
| 52 Week Range | 0.3100 - 3.0500 |
| Volume | |
| Avg. Volume | 1,573 |
| Market Cap | 34.73M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.90 |
NewsfileMedicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - May 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed the first closing of its previously announced private placement (the "Private Placement") of 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). The Company issued US$5,172,500 aggregate principal amount of Notes in the first closing, which was unbrokered. The Company may issue additional Notes in one or more further ...
NewsfileMedicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - April 25, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it intends to complete the first closing of a private placement (the "Private Placement") of its 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). Approximately US$5,172,500 aggregate principal amount of Notes will be issued at the first closing, which is expected to occur on or about May 1st , 2024, ...
NewsfileMedicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
FDA Agrees with the Study Design of Randomizing Up To 60 Participants with Nodular Type of Basal Cell Carcinoma Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce the receipt of comments from the U.S Food and Drug Administration (FDA).The clinical non-hold comments from the FDA consider the results of the study exploratory and request the Company to provide data from clinical studies ...
